Last reviewed · How we verify

magnesium sulphate& levobupivacaine — Competitive Intelligence Brief

magnesium sulphate& levobupivacaine (magnesium sulphate& levobupivacaine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker, Local anesthetic. Area: Anesthesiology.

phase 3 Calcium channel blocker, Local anesthetic Calcium channels, Sodium channels Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

magnesium sulphate& levobupivacaine (magnesium sulphate& levobupivacaine) — South Egypt Cancer Institute. Magnesium sulphate acts as a calcium channel blocker, while levobupivacaine is a local anesthetic that blocks sodium channels.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
magnesium sulphate& levobupivacaine TARGET magnesium sulphate& levobupivacaine South Egypt Cancer Institute phase 3 Calcium channel blocker, Local anesthetic Calcium channels, Sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker, Local anesthetic class)

  1. South Egypt Cancer Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). magnesium sulphate& levobupivacaine — Competitive Intelligence Brief. https://druglandscape.com/ci/magnesium-sulphate-levobupivacaine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: